Crinetics Pharmaceuticals, Inc.
- Open
- 84.96
- Day high
- 85.03
- Day low
- 84.92
- Prev close
- 84.84
- Volume
- 8.2M
- Mkt cap
- $9.0B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 7.6
- P/S
- 213.8
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$366K over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions accumulating (13F)
Crinetics Pharmaceuticals, Inc. (CRNX) is a Healthcare company listed on NASDAQ. The stock is up 155% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
Crinetics Pharmaceuticals, Inc. (CRNX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 10 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CRNX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $-1.18 | $-1.14 | +3.4% | $25M | +69.2% |
| May 7, 2026 | $-1.22 | $-1.23 | -0.8% | $11M | +26.1% |
| Nov 6, 2025 | $-1.27 | $-1.38 | -8.7% | $143000 | -96.7% |
| Aug 7, 2025 | $-1.13 | $-1.23 | -8.8% | $1M | +161.7% |
| May 8, 2025 | $-0.99 | $-1.04 | -5.1% | $361000 | +3.8% |
| Feb 27, 2025 | $-0.92 | $-0.88 | +4.3% | — | — |
| Aug 8, 2024 | $-0.86 | $-0.94 | -9.3% | $399000 | -21.8% |
| May 9, 2024 | $-0.84 | $-0.93 | -10.7% | $640000 | +146.2% |
| Feb 28, 2024 | $-0.89 | $-0.90 | -1.1% | — | — |
| May 4, 2023 | $-0.82 | $-0.85 | -3.7% | $3M | +325.2% |
| Feb 28, 2023 | $-0.82 | $-0.84 | -2.4% | $709000 | +183.6% |
| Nov 14, 2022 | $-0.78 | $-0.78 | +0.0% | $458000 | +83.2% |
CRNX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 24, 2026 | Schilke Tobinofficer: Chief Financial & Infra. Ofcr. | Grant | 471 | — |
| Aug 11, 2026 | Struthers Richard Scottdirector, officer: President & CEO | Option | 6,542 | $15.29 |
| Aug 11, 2026 | Struthers Richard Scottdirector, officer: President & CEO | Option | 4,422 | $22.61 |
| Aug 11, 2026 | Struthers Richard Scottdirector, officer: President & CEO | Option | 3,969 | $25.19 |
| Aug 11, 2026 | Struthers Richard Scottdirector, officer: President & CEO | Option | 4,995 | $20.02 |
| Jul 7, 2026 | Vivaldi Coelho Rogeriodirector | Sell | 3,000 | $40.00 |
| Jun 22, 2026 | Nichols Westondirector | Grant | 9,730 | $35.87 |
| Jun 22, 2026 | Okey Stephaniedirector | Grant | 5,925 | — |
| Jun 22, 2026 | Fust Matthew Kdirector | Grant | 5,925 | — |
| Jun 22, 2026 | Vivaldi Coelho Rogeriodirector | Grant | 5,925 | — |
| Jun 22, 2026 | Bedrosian Camille Ldirector | Grant | 9,730 | $35.87 |
| Jun 22, 2026 | Bedrosian Camille Ldirector | Grant | 5,925 | — |
| Jun 22, 2026 | Nichols Westondirector | Grant | 5,925 | — |
| Jun 22, 2026 | Vivaldi Coelho Rogeriodirector | Grant | 9,730 | $35.87 |
| Jun 22, 2026 | WIERENGA WENDELLdirector | Grant | 9,730 | $35.87 |
Source: CRNX SEC Form 4 filings, latest Aug 24, 2026. For informational purposes only — not investment advice.
See the full CRNX insider & 13F page →Crinetics Pharmaceuticals, Inc. company profile
Overview
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in San Diego, California. The company went public in July 2018 and focuses on developing innovative oral therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics has built a robust pipeline centered around nonpeptide small molecule drugs that target hormone receptors, with its lead candidate paltusotine nearing FDA approval for acromegaly treatment. The company has evolved from a research-focused organization to one preparing for commercial launch, with substantial cash reserves of approximately $1.4 billion to fund operations through 2029.
Business
Crinetics operates in the rare endocrine disease therapeutics market, developing oral alternatives to existing injectable treatments for hormone-related disorders. The endocrine system regulates hormones throughout the body, and when this system malfunctions, it can cause serious chronic conditions that currently require frequent injections or complex treatment regimens. The company's core technology platform focuses on nonpeptide small molecule drugs that can be taken orally, offering significant advantages over current peptide-based injectable therapies. These oral drugs target specific hormone receptors to regulate hormone production and activity in the body. Paltusotine is the company's lead product candidate, an oral somatostatin receptor type 2 agonist for treating acromegaly - a rare condition where the pituitary gland produces too much growth hormone, causing abnormal enlargement of body parts. Current treatments require regular injections, while paltusotine offers the convenience of oral dosing. The drug has completed Phase III trials and has an FDA approval decision expected by September 2025. Paltusotine is also being studied for carcinoid syndrome, a condition associated with certain neuroendocrine tumors that causes flushing and diarrhea. Atumelnant (formerly CRN04894) is the company's second major candidate, targeting Congenital Adrenal Hyperplasia (CAH) and Cushing's disease. CAH is a genetic disorder affecting cortisol production, while Cushing's disease involves excess cortisol production. Both conditions currently require lifelong steroid treatments with significant side effects. The company's early-stage pipeline includes a TSH antagonist for Graves' disease and thyroid eye disease, programs targeting parathyroid hormone disorders, and a novel Non-Peptide Drug Conjugate (NDC) platform for targeted cancer therapy. Revenue is currently minimal, derived primarily from research collaborations, with the Eli Lilly partnership for radiopharmaceuticals representing a significant milestone ($140 million upfront with potential $1 billion purchase price).
Revenue model
Crinetics' business model is built around developing and commercializing proprietary oral therapeutics for rare endocrine diseases, with revenue expected to come primarily from product sales once drugs reach market. The company currently generates minimal revenue from research collaborations and licensing agreements, with most income coming from the Eli Lilly partnership for its radiopharmaceuticals program. The primary revenue model will be direct product sales to specialty pharmacies and healthcare providers treating rare endocrine conditions. The target customer base consists of specialized endocrinologists, pituitary treatment centers, and academic medical centers that treat patients with rare hormone disorders. These markets are highly concentrated, with approximately 200 healthcare practitioners in the US treating the majority of acromegaly patients, making the commercial strategy focused and efficient. Pricing power is expected to be strong due to the rare disease nature of the target conditions and the significant advantages of oral therapy over current injectable treatments. The company's value proposition centers on improved patient compliance, reduced treatment burden, and potentially lower overall healthcare costs through better disease management. Factors that could increase margins include successful market penetration with premium pricing for breakthrough oral therapies, expansion into additional indications for existing drugs, and leveraging the same commercial infrastructure across multiple products. The concentrated nature of the treatment centers allows for efficient sales force deployment with just 25-30 representatives initially. Factors that could pressure margins include competitive pressure from other oral alternatives, pricing pressure from payers despite the rare disease setting, higher-than-expected clinical trial costs for expanding indications, and the need for extensive patient support programs. Manufacturing costs for complex small molecules and the requirement for specialized distribution channels could also impact profitability. Additionally, the company faces the typical biotech challenge of high upfront development costs that must be recouped through future product sales.
Competitive moat
Crinetics possesses a moderate but developing competitive moat based on several key factors. The company's primary competitive advantage lies in its proprietary expertise in developing nonpeptide small molecule drugs for hormone receptor targets, which is technically challenging and requires specialized knowledge in both endocrinology and medicinal chemistry. The intellectual property portfolio around paltusotine and other candidates provides patent protection, though the strength and duration of this protection varies by program. More importantly, the company has built significant regulatory expertise and clinical relationships in rare endocrine diseases, which creates barriers for new entrants who would need to replicate years of clinical development and regulatory interactions. The concentrated treatment landscape creates a natural moat, as there are only about 200 key healthcare practitioners treating acromegaly patients in the US. Once Crinetics establishes relationships with these specialists and demonstrates clinical efficacy, it becomes difficult for competitors to displace them. The rare disease setting also means that physicians are conservative about switching treatments once they find effective options. However, the moat faces several potential threats. Large pharmaceutical companies with greater resources could develop competing oral therapies or acquire smaller competitors. The success of paltusotine could validate the oral approach and attract more investment into the space. Additionally, if current injectable therapies develop oral formulations or improved delivery methods, they could maintain their market positions. The company's early-stage pipeline programs face more competition risk, as they are further from market and competing against both established treatments and other development-stage companies. The technical complexity of developing effective nonpeptide hormone receptor modulators provides some protection, but this advantage diminishes as the scientific understanding in this area advances and more companies gain expertise. Overall, Crinetics has built a solid foundation for competitive advantage, but the moat will ultimately depend on successful commercial execution and continued innovation in their core technology platform.
Risks & safety
Crinetics demonstrates a strong financial safety profile typical of a well-funded clinical-stage biotech company approaching commercialization. • Cash Position: $1.4 billion in cash and investments as of Q1 2025, providing runway through 2029 • Debt Level: Minimal debt with debt-to-equity ratio of 0.04, indicating very low financial leverage • Current Ratio: 22.5x current ratio shows excellent short-term liquidity • Cash Burn: Quarterly operating cash flow of -$88.5 million in Q1 2025, manageable given cash position • Valuation Metrics: - Price-to-book ratio of 2.49x appears reasonable for a late-stage biotech - Negative earnings metrics due to pre-revenue status are typical for the sector - Enterprise value reflects substantial cash position • Other Considerations: Primary risk is binary FDA approval outcome for paltusotine, with significant commercial infrastructure investment already committed. Strong balance sheet provides cushion for potential regulatory delays or additional clinical requirements. Revenue diversification limited until multiple products reach market.
Recent development
Over the past few years, Crinetics has transformed from a research-focused company to one preparing for commercial launch. The most significant development has been the progression of paltusotine through Phase III trials for acromegaly, with successful completion of both PATHFNDR-1 and PATHFNDR-2 studies leading to NDA submission and expected FDA approval by September 2025. The company has significantly expanded its pipeline beyond the original paltusotine program. Atumelnant has advanced through Phase II trials for both CAH and Cushing's disease, with Phase III studies planned for 2025. The CAH program represents a particularly innovative approach, using a composite primary endpoint designed to demonstrate the drug's ability to normalize hormone levels while reducing dependence on glucocorticoids. Commercial infrastructure development has been a major focus, with the company building a specialized sales force of approximately 30 representatives targeting the concentrated network of pituitary treatment centers. The launch of the CrinetiCare patient support platform and disease awareness campaigns demonstrates preparation for market entry. The company has also diversified its technology platform through the introduction of Non-Peptide Drug Conjugates (NDCs) for targeted cancer therapy, representing an expansion beyond endocrine diseases. The partnership with Eli Lilly for radiopharmaceuticals ($140 million upfront, potential $1 billion purchase price) validates the company's broader technology capabilities. International expansion has begun with establishment of European operations and plans for Market Authorization Application (MAA) submission in the first half of 2025. The company is initially focusing on Germany as the primary European market, with potential expansion to Brazil representing the Latin American opportunity. Pipeline expansion has accelerated with four IND filings planned for 2025, including programs targeting TSH receptors for Graves' disease, parathyroid hormone for hyperparathyroidism, and SST3 agonists for autosomal dominant polycystic kidney disease. This diversification reduces dependence on any single program while leveraging the company's core expertise in hormone receptor modulation.
CRNX company profile · for informational purposes only — not investment advice.
Track CRNX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free